With the exception of two studies (Fourlanos et al., 2011; Roep et al., 2013), all the clinical trials based on insulin administration by different ways failed to preserve the residual β cell mass once the autoimmune attack has induced patent T1D. This evidence concerns the gene INS and type 1 diabetes mellitus.